{
    "id": 6095,
    "fullName": "NF1 loss",
    "impact": "unknown",
    "proteinEffect": "loss of function",
    "geneVariantDescriptions": [
        {
            "description": "NF1 loss indicates loss of the NF1 gene, mRNA, and protein.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "non-specific",
    "gene": {
        "id": 4763,
        "geneSymbol": "NF1",
        "terms": [
            "NF1",
            "NFNS",
            "VRNF",
            "WSS"
        ]
    },
    "variant": "loss",
    "createDate": "05/14/2015",
    "updateDate": "09/19/2019",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 2186,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, glioma cells with a loss of NF1 expression were resistant to growth inhibition by Rapamune (sirolimus) (PMID: 21216928).",
            "molecularProfile": {
                "id": 5927,
                "profileName": "NF1 loss"
            },
            "therapy": {
                "id": 917,
                "therapyName": "Sirolimus",
                "synonyms": null
            },
            "indication": {
                "id": 60108,
                "name": "brain glioma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2720,
                    "pubMedId": 21216928,
                    "title": "Interpreting mammalian target of rapamycin and cell growth inhibition in a genetically engineered mouse model of Nf1-deficient astrocytes.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/21216928"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8491,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Selumetinib (AZD-6244) inhibited proliferation of melanoma cells harboring NF1 loss in culture (PMID: 26438159).",
            "molecularProfile": {
                "id": 5927,
                "profileName": "NF1 loss"
            },
            "therapy": {
                "id": 913,
                "therapyName": "Selumetinib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4382,
                    "pubMedId": 26438159,
                    "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438159"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2182,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, the MEK inhibitor PD-0325901 reduced proliferation and colony formation in sarcoma cell lines with a loss of NF1 expression (PMID: 23858101).",
            "molecularProfile": {
                "id": 5927,
                "profileName": "NF1 loss"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 1115,
                "name": "sarcoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2710,
                    "pubMedId": 23858101,
                    "title": "NF1 deletion generates multiple subtypes of soft-tissue sarcoma that respond to MEK inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23858101"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2183,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, treatment with PD-0325901 inhibited tumor growth in mouse models of neurofibroma with NF1 loss of expression (PMID: 23221341).",
            "molecularProfile": {
                "id": 5927,
                "profileName": "NF1 loss"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 962,
                "name": "neurofibroma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2711,
                    "pubMedId": 23221341,
                    "title": "MEK inhibition exhibits efficacy in human and mouse neurofibromatosis tumors.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23221341"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14178,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Ralimetinib (LY2228820) did not preferentially inhibited growth of NF1 null transformed cells compared to NF1 wild-type cells in culture (J Clin Oncol 36, 2018 (suppl; abstr e24284)).",
            "molecularProfile": {
                "id": 5927,
                "profileName": "NF1 loss"
            },
            "therapy": {
                "id": 3296,
                "therapyName": "Ralimetinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11489,
                    "pubMedId": null,
                    "title": "Effect of the loss of NF1 in breast cancer on pathway activation.",
                    "url": "https://meetinglibrary.asco.org/record/164427/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8462,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RO4987655 inhibited proliferation of melanoma cells harboring NF1 loss in culture (PMID: 26438159).",
            "molecularProfile": {
                "id": 5927,
                "profileName": "NF1 loss"
            },
            "therapy": {
                "id": 903,
                "therapyName": "RO4987655",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4382,
                    "pubMedId": 26438159,
                    "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438159"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14177,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Zelboraf (vemurafenib) did not preferentially inhibited growth of NF1 null transformed cells compared to NF1 wild-type cells in culture (J Clin Oncol 36, 2018 (suppl; abstr e24284)).",
            "molecularProfile": {
                "id": 5927,
                "profileName": "NF1 loss"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11489,
                    "pubMedId": null,
                    "title": "Effect of the loss of NF1 in breast cancer on pathway activation.",
                    "url": "https://meetinglibrary.asco.org/record/164427/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14174,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Mekinist (trametinib) preferentially inhibited growth of NF1 null transformed cells compared to NF1 wild-type cells in culture (J Clin Oncol 36, 2018 (suppl; abstr e24284)).",
            "molecularProfile": {
                "id": 5927,
                "profileName": "NF1 loss"
            },
            "therapy": {
                "id": 2,
                "therapyName": "Trametinib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11489,
                    "pubMedId": null,
                    "title": "Effect of the loss of NF1 in breast cancer on pathway activation.",
                    "url": "https://meetinglibrary.asco.org/record/164427/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14176,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Nexavar (sorafenib) did not preferentially inhibited growth of NF1 null transformed cells compared to NF1 wild-type cells in culture (J Clin Oncol 36, 2018 (suppl; abstr e24284)).",
            "molecularProfile": {
                "id": 5927,
                "profileName": "NF1 loss"
            },
            "therapy": {
                "id": 920,
                "therapyName": "Sorafenib",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "no benefit",
            "references": [
                {
                    "id": 11489,
                    "pubMedId": null,
                    "title": "Effect of the loss of NF1 in breast cancer on pathway activation.",
                    "url": "https://meetinglibrary.asco.org/record/164427/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 14175,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD-0325901 preferentially inhibited growth of NF1 null transformed cells compared to NF1 wild-type cells in culture (J Clin Oncol 36, 2018 (suppl; abstr e24284)).",
            "molecularProfile": {
                "id": 5927,
                "profileName": "NF1 loss"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 10000003,
                "name": "Advanced Solid Tumor",
                "source": "JAX"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 11489,
                    "pubMedId": null,
                    "title": "Effect of the loss of NF1 in breast cancer on pathway activation.",
                    "url": "https://meetinglibrary.asco.org/record/164427/abstract"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 8479,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, RO5126766 inhibited proliferation of melanoma cells harboring NF1 loss in culture (PMID: 26438159).",
            "molecularProfile": {
                "id": 5927,
                "profileName": "NF1 loss"
            },
            "therapy": {
                "id": 2011,
                "therapyName": "RO5126766",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 4382,
                    "pubMedId": 26438159,
                    "title": "ERK Signal Suppression and Sensitivity to CH5183284/Debio 1347, a Selective FGFR Inhibitor.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26438159"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2184,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human melanoma cell lines harboring BRAF activating mutations and loss of NF1 were resistant to treatment with Zelboraf (vemurafenib) in culture and in xenograft models (PMID: 23171796).",
            "molecularProfile": {
                "id": 5928,
                "profileName": "BRAF act mut NF1 loss"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 2712,
                    "pubMedId": 23171796,
                    "title": "Elucidating distinct roles for NF1 in melanomagenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23171796"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 2185,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, PD-0325901 inhibited growth of melanoma cells derived from NF1-null and BRAF mutant mouse models in culture and in allograft animal models (PMID: 23171796).",
            "molecularProfile": {
                "id": 5928,
                "profileName": "BRAF act mut NF1 loss"
            },
            "therapy": {
                "id": 849,
                "therapyName": "PD-0325901",
                "synonyms": null
            },
            "indication": {
                "id": 1909,
                "name": "melanoma",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 2712,
                    "pubMedId": 23171796,
                    "title": "Elucidating distinct roles for NF1 in melanomagenesis.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/23171796"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 5927,
            "profileName": "NF1 loss",
            "profileTreatmentApproaches": [
                {
                    "id": 4543,
                    "name": "MEK2 Inhibitor",
                    "profileName": "NF1 loss"
                },
                {
                    "id": 4544,
                    "name": "mTOR Inhibitor",
                    "profileName": "NF1 loss"
                },
                {
                    "id": 4541,
                    "name": "MEK inhibitor (Pan)",
                    "profileName": "NF1 loss"
                },
                {
                    "id": 4542,
                    "name": "MEK1 Inhibitor",
                    "profileName": "NF1 loss"
                }
            ]
        },
        {
            "id": 5928,
            "profileName": "BRAF act mut NF1 loss",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}